Glenzocimab (ACT-017)

About Acticor Biotech

Acticor Biotech is a clinical-stage biopharmaceutical company developing a new class of drugs for acute thrombotic events, with a primary focus on ischemic stroke. Its lead asset, glenzocimab, is a humanized monoclonal antibody fragment targeting platelet glycoprotein VI (GPVI), offering a potentially safer mechanism of action by inhibiting pathological thrombus formation without affecting physiological hemostasis. The company is advancing its candidate through international clinical trials, most notably the Phase 2/3 ACTISAVE study in acute ischemic stroke. Acticor operates as a public company, leveraging strategic partnerships to advance its pipeline and address a significant unmet medical need in a large global market.

About Acticor Biotech

Acticor Biotech is a clinical-stage biopharmaceutical company developing a new class of drugs for acute thrombotic events, with a primary focus on ischemic stroke. Its lead asset, glenzocimab, is a humanized monoclonal antibody fragment targeting platelet glycoprotein VI (GPVI), offering a potentially safer mechanism of action by inhibiting pathological thrombus formation without affecting physiological hemostasis. The company is advancing its candidate through international clinical trials, most notably the Phase 2/3 ACTISAVE study in acute ischemic stroke. Acticor operates as a public company, leveraging strategic partnerships to advance its pipeline and address a significant unmet medical need in a large global market.

Therapeutic Areas

Other Acute Ischemic Stroke Drugs